Evidence map›Paper›PMID 26523992›Full record

ArticleAtherosclerosis2015

Soluble endothelial cell selective adhesion molecule and cardiovascular outcomes in patients with stable coronary disease: A report from the Heart and Soul Study.

Meyeon Park, Ameya Kulkarni, Alexis Beatty, Peter Ganz, Mathilda Regan, Eric Vittinghoff, Mary Whooley

Abstract read
In one paragraph

Article in Atherosclerosis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Meyeon ParkDivision of Nephrology, University of California, San Francisco (UCSF), San Francisco, CA, USA. Electronic address: meyeon.park@ucsf.edu.
Ameya KulkarniKaiser Permanente, McLean, VA, USA.
Alexis BeattyDivision of Cardiology, VA Puget Sound Health Care System, University of Washington, USA.
Peter GanzDivision of Cardiology, VA Puget Sound Health Care System, University of Washington, USA; Division of Cardiology, University of California San Francisco and San Francisco General Hospital, USA.
Mathilda ReganDepartment of Medicine, San Francisco VA Hospital, San Francisco, CA, USA.
Eric VittinghoffDepartment of Epidemiology and Biostatistics, UCSF, San Francisco, CA, USA.
Mary WhooleyDepartment of Medicine, San Francisco VA Hospital, San Francisco, CA, USA; Department of Medicine, UCSF, San Francisco, CA, USA; Department of Epidemiology and Biostatistics, UCSF, San Francisco, CA, USA.
University of California, San Francisco · USKaiser Permanente · USSan Francisco VA Medical Center · USUniversity of Washington · USVA Puget Sound Health Care System · US

Funding

Epidemiology of Depression and Heart Failure in AgingR01HL079235 · NHLBI · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WHOOLEY, MARY A · 2005 to 2009
$4.2M
Why do patients with cardiovascular disease develop kidney injury and disease?K23DK099238 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PARK, MEYEON · 2013 to 2017
$928k
NHLBI NIH HHS R01 HL-079235NHLBI NIH HHS R01 HL079235NIDDK NIH HHS K23 DK099238NIDDK NIH HHS K23DK099238
6 · The paper itself

Abstract

BACKGROUND AND

aimsEndothelial cell-selective adhesion molecule (ESAM) is selectively expressed on vascular endothelium and is postulated to play a role in atherogenesis. We investigated the association of serum soluble ESAM (sESAM) levels with subsequent cardiovascular outcomes in patients with stable ischemic heart disease.

methodsWe measured sESAM levels in 981 patients with stable coronary disease enrolled between September 2000 and December 2002 in a prospective cohort study. Poisson regression models were used to define the relationship between baseline sESAM levels and cardiovascular outcomes, including myocardial infarction, heart failure hospitalization, and mortality.

resultsThere were 293 occurrences of the composite endpoint over a median follow-up of 8.9 years. After adjusting for demographic and clinical risk factors, participants in the highest sESAM quartile (compared to the lower three sESAM quartiles) had a higher rate of the composite endpoint (incident rate ratio (IRR) 1.52 (95% CI 1.16-1.99) as well as of its individual components: myocardial infarction (IRR 1.64 (1.06-2.55)), heart failure hospitalizations (IRR 1.96 (1.32-2.81)), and death (IRR 1.5 (1.2-1.89)). These associations were no longer significant after adjustment for estimated glomerular filtration rate.

conclusionssESAM levels associate with myocardial infarction, heart failure, and death after adjustment for demographic and clinical risk factors, but not after adjustment for kidney function. sESAM may be involved in the pathogenesis of concurrent kidney and cardiovascular disease.

Indexed as

AdultAgedBiomarkersCell Adhesion MoleculesChi-Square DistributionCoronary Artery DiseaseDisease ProgressionFemaleGlomerular Filtration RateHeart FailureHospitalizationHumansIncidenceKidneyMaleMiddle AgedBiomarkersCell Adhesion MoleculesESAM protein, humanAtherosclerosisCardiovascular mortalityEndotheliumKidney disease

Identifiers

PMID26523992
PMCPMC4663109
OpenAlexW1801266933

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.